|1.47||-0.0200||-1.34%||Vol 21.92M||1Y Perf -72.81%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||0.02 1.36%|
|Target Price||2.39||Analyst Rating||Moderate Buy 2.50|
|Potential %||62.59||Finscreener Ranking||☆ 34.61|
|Insiders Trans % 3/6/12 mo.||-/-100/-80||Value Ranking||+ 35.15|
|Insiders Value % 3/6/12 mo.||-/-100/100||Growth Ranking||★ 37.83|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/100||Income Ranking||— -|
|Price Range Ratio 52W %||19.53||Earnings Rating||Strong Sell|
|Market Cap||247.50M||Earnings Date||8th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.36|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.63M|
|Avg. Monthly Volume||2.21M|
|Avg. Quarterly Volume||3.50M|
Epizyme Inc. (NASDAQ: EPZM) stock closed at 1.47 per share at the end of the most recent trading day (a -1.34% change compared to the prior day closing price) with a volume of 21.92M shares and market capitalization of 247.50M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 304 people. Epizyme Inc. CEO is Robert B. Bazemore.
The one-year performance of Epizyme Inc. stock is -72.81%, while year-to-date (YTD) performance is -41.2%. EPZM stock has a five-year performance of -88.78%. Its 52-week range is between 0.41095 and 5.8341, which gives EPZM stock a 52-week price range ratio of 19.53%
Epizyme Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 14.84, a price-to-sale (PS) ratio of 9.78, a price to cashflow ratio of 31.10, a PEG ratio of 2.32, a ROA of -67.89%, a ROC of -82.89% and a ROE of -828.49%. The company’s profit margin is -%, its EBITDA margin is -537.50%, and its revenue ttm is $25.48 Million , which makes it $0.15 revenue per share.
Of the last four earnings reports from Epizyme Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.36 for the next earnings report. Epizyme Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Epizyme Inc. is Moderate Buy (2.5), with a target price of $2.39, which is +62.59% compared to the current price. The earnings rating for Epizyme Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Epizyme Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Epizyme Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.04, ATR14 : 0.04, CCI20 : -58.82, Chaikin Money Flow : -0.27, MACD : 0.06, Money Flow Index : 10.19, ROC : -0.68, RSI : 64.52, STOCH (14,3) : 25.00, STOCH RSI : 0.00, UO : 50.25, Williams %R : -75.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Epizyme Inc. in the last 12-months were: Jeffery Kutok (Sold 2 556 shares of value $3 502 ), Jeffery L. Kutok (Sold 5 297 shares of value $5 969 ), Joseph Beaulieu (Sold 909 shares of value $1 274 ), Pablo Legorreta (Buy at a value of $34 000 000), Shefali Agarwal (Sold 9 541 shares of value $17 007 )
Fri, 03 Jun 2022 10:15 GMT Analysts Are Bullish on Top Healthcare Stocks: Epizyme (EPZM), Aptose Biosciences (APTO)- TipRanks. All rights reserved.
Thu, 12 May 2022 10:26 GMT Epizyme (EPZM) Gets a Buy Rating from H.C. Wainwright- TipRanks. All rights reserved.
Sat, 15 Jan 2022 01:51 GMT Epizyme (EPZM) Receives a Buy from Barclays- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.